What it is
Regulatory status: prescription medication
Evidence basis: Human clinical evidence
Bempedoic acid inhibits ATP-citrate lyase upstream of cholesterol synthesis, while ezetimibe reduces intestinal cholesterol absorption. The fixed-dose tablet combines 180 mg and 10 mg respectively.
What it is, why people use it, the evidence, and what to know before trying it.
Regulatory status: prescription medication
Evidence basis: Human clinical evidence
Contraindications, interactions and clinical cautions from reviewed sources.
Important risks include hyperuricemia, gout, tendon rupture, and gallstones. Interactions and indication details must be checked against the current label and the patient's other lipid medicines.
This review does not automatically apply to:
Public protocols that include Nexlizet. Open one to see the full context and source.
Dose and frequency not stated. The Drive
Ongoing prescription under medical supervision as of 10 Sep 2025; not a recommendation.
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
Continue into interventions that appear alongside this one.